Mountain View, CA, October 4, 2004
IMPAC Medical Systems,
Inc. (NASDAQ:IMPCE), a leading provider of information technology
solutions for oncology care, and Elekta, a world-leading supplier
of advanced and innovative radiation oncology solutions and
services, announce today their agreement to collaborate on future
development of enhanced interfaces to connect the Elekta product
lines of digital linear accelerators (Elekta Synergy® and Precise
Treatment System®) with IMPAC’s oncology information management
products.
A new enhanced interface is expected to ship later this year which
will add a high speed capability supportive of Elekta’s
PreciseBEAM™ IMRT. This high-speed performance enhancement will
also be included in the DICOM-RT compliant linear accelerator
interface
the companies are jointly developing. IMPAC and Elekta were the
first two companies to formally endorse and adopt the emerging
DICOM-RT linear accelerator interface standard.
“This is a collaborative development effort aimed at enhancing the
process of delivering increasingly complex cancer treatments,”
stated Joseph K. Jachinowski, president and CEO of IMPAC. “IMPAC
is pleased to be working with Elekta to develop the next
generation of advanced image guided IMRT treatments,” he added.
“This agreement will further improve seamless connectivity for
customers by expanding the use of new technology systems –
offering our customers true integration along with the freedom to
choose the products which best fit their needs,” stated Laurent
Leksell, president and CEO of Elekta. “More importantly, patients
will benefit from an efficient and effective delivery of leading
edge treatments.”
About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc. is a leading provider of oncology IT
solutions that streamline both clinical and business operations to
help improve the process of delivering quality patient care. With
systems designed for anatomic pathology, medical oncology,
radiation oncology, imaging, clinical laboratory, and cancer
registry, IMPAC supports the entire team of healthcare
professionals who contribute to the care of the cancer patient.
Supporting more than 2500 installations worldwide, IMPAC provides
practical solutions that deliver better overall communication,
process efficiency and quality patient care. For more information
about IMPAC’s products or services, please call 888-GO-IMPAC or
visit www.impac.com.
About Elekta
Elekta is a world-leading supplier of advanced and innovative
radiation oncology and neurosurgery solutions and services for
precise treatment of cancer and brain disorders. Elekta’s
solutions are clinically effective, cost efficient and gentle on
the patient. For additional information about Elekta, please visit
www.elekta.com.
The statements contained in this press
release that are not purely historical are forward looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, including statements regarding the Company's
expectations, beliefs, hopes, intentions or strategies regarding
the future. Forward looking statements include statements
regarding the Company's review of its revenue recognition policies
and the estimated impact of the proposed financial restatement of
previously report results, possible delisting from The NASDAQ
Stock Market, business strategy, timing of, and plans for, the
introduction of new products and enhancements, future sales,
market growth and direction, competition, market share, revenue
growth, operating margins and profitability. All forward looking
statements included in this document are based upon information
available to the Company as of the date hereof, and the Company
assumes no obligation to update any such forward looking
statement. Actual results could differ materially from the
Company's current expectations. Factors that could cause or
contribute to such differences include the Company's ability to
expand outside the radiation oncology market or expand into
international markets, our inability to recognize revenue from
multiple element software contracts where certain elements have
been delivered, installed and accepted but other elements remain
undelivered, lost sales or lower sales prices due to competitive
pressures, the ability to integrate its products successfully with
related products and systems in the medical services industry,
reliance on distributors and manufacturers of oncology equipment
to market its products, changes in Medicare reimbursement
policies, the integration and performance of acquired businesses,
and other factors and risks discussed in the 10 K/A and other
reports filed by the Company from time to time with the Securities
and Exchange Commission. |
